US20060148007A1 - Method for using division arrested cells in screening assays - Google Patents
Method for using division arrested cells in screening assays Download PDFInfo
- Publication number
- US20060148007A1 US20060148007A1 US11/363,983 US36398306A US2006148007A1 US 20060148007 A1 US20060148007 A1 US 20060148007A1 US 36398306 A US36398306 A US 36398306A US 2006148007 A1 US2006148007 A1 US 2006148007A1
- Authority
- US
- United States
- Prior art keywords
- cell
- cells
- type
- substance
- interest
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
Definitions
- This invention relates to methods for screening for substances of interest. More particularly, it relates to screening assays which utilize cells in a division arrested state which, nonetheless, function effectively in assays where dividing cells would normally be used.
- screening assays which utilize cells in a division arrested state which, nonetheless, function effectively in assays where dividing cells would normally be used.
- Cell based screening assays are tools well known to biologists. In the assays, one investigates compounds of interest to determine, e.g. if the compounds modulate one or more biological processes of interest.
- cell based systems which are used are those which measure reporter activity, calcium activity assay, and so forth. These, and all other cell based assays are encompassed by the invention.
- cell based screening assays One area where cell based screening assays have become widely accepted is the high throughput analysis of materials for use as pharmaceuticals. These assays are useful and desirable because compounds which are identified initially in biochemical assays have been known to fail as drug candidates later in the development process. The reasons for this are many. In some cases, the compound does not permeate the cell readily. In others, target binding capability is not predictive of the target modulating function, a feature that is, ultimately, a requirement of drug functions. Cell based screening assays are useful in that they address a number of problems associated with animal model testing (e.g., high expense, intensive labor, long assay period). High throughput cell based screening assays can be scaled up via technologies such as “FLIPR,” “Leedseeker,” “VIPR,” and fluorescent, high speed cell-imaging.
- technologies such as “FLIPR,” “Leedseeker,” “VIPR,” and fluorescent, high speed cell-imaging.
- cell based assays involve enzyme-reporter systems, cell activity assays with a fluorescent or colorimetric readout, and so forth.
- An example of such an assay is a Ca 2+ mobilization assay to measure G-protein coupled receptor activity with the dye “Fluo-4.”
- cell based assays have a distinct advantage in that they permit the user to determine the functional outcome of the use of compounds. Properly designed assays also permit the artisan to select against the toxic compounds, when screening for active ones.
- Actively managed cell culture cycles have a recovery phase, when they are split from near confluent cultures, followed by an early log growth phase, then a mid log, and a late log phase, leading to a stationary phase if the culture is allowed to become confluent.
- Variances of the cellular processes and protein components at these different stages of growth and replication occur constantly during these cell cultures as cells cycle through mitosis. These variances must be expected to affect biological assays, and be a factor in the common phenomenon of variability in high throughput assays.
- One, but by no means the only example of this, relates to the length of time over which assays are run. There is generally an 8-36 hour period following the seeding of cells during which the assay is run. The cells in the particular culture go through different phases of their culture cycle during this time, and it is not usual for the cells to be at the same point in the cycle at the same time.
- the critical factors of a good cell based screening assay are (i) a well validated target, (ii) a sensitive readout, and (iii) extremely high consistency of the cells that are used.
- the invention which is set forth in the disclosure which follows addresses this third issue.
- the consistent performance of the cells in an assay can be greatly affected by changes in the level of target expression as a result of increasing cell passage number.
- a well characterized population of cells can be division arrested, cryopreserved as a cell bank, and plated for an assay without any additional passaging of the cells.
- division arrested cells may be plated and used over a period of up to five (5) days without any further handling of the cells and without a significant change in cell based responses.
- FIG. 1 sets forth FACS scans depicting serotonin induction of Ca ++ mobilization on division arrested cells, which are set forth in example 1.
- FIG. 2 shows the result of experiments, described in detail in example 2. It shows carbachol induced, Ca 2+ mobilization, observed via changes in fluorescent emission ratios of Fura2 loaded into cells that were induced.
- FIG. 3 summarizes the result of experiments set forth in example 3, involving cells where division was arrested by irradiation, and which were treated with isoproterenol and reporter gene changes were measured.
- NIH3T3 cells were stably transfected with cDNA encoding the known receptor “5HT2c” using standard methods. For information on the receptor, see Julius, et al., Proc. Natl. Acad. Sci USA 87(3):928-32 (1990), incorporated by reference. After the transfection, and a preliminary screen to make sure that the transfection was successful, NIH3T3 cells which expressed the receptor were grown in DMEM, with L-glutamine without NaPyruvate, and with L-glucose (4500 mg/L), together with 1 ⁇ penicillin-streptomycin solution and 10% (v/v) fetal bovine serum (FBS). This cell line is referred to as “NIH3T3-P0P.”
- Mitomycin C is well known for its ability to arrest cell growth by blocking microtubule mobility, thereby arresting cell division.
- the cells were frozen, 2.5 hours after treatment, using standard protocols.
- Cells were loaded with Indo-1 AM dye by adding 2 mg/ml of Indo-1 AM stock, in DMSO, to the cell suspensions to a final concentration of 10 ug/1.2 mls. Cells were exposed to Indo-1 AM for seven (7) minutes at room temperature and then diluted up to a final volume of 10 mls with Indo-1 loading buffer and pelleted.
- Cells were resuspended in a buffer and loaded into a syringe. Cells were injected continuously into the flow cytometer to be sampled and to provide a baseline value. A substance such as an antagonist can be used to pretreat the cells, with a second material, such as an agonist being injected continuously and simultaneously through, e.g., a second syringe, via a connecting means, such as a standard Y-connector. Cells are then exposed to the test substance, analyzed, and changes from baseline measured.
- a substance such as an antagonist can be used to pretreat the cells, with a second material, such as an agonist being injected continuously and simultaneously through, e.g., a second syringe, via a connecting means, such as a standard Y-connector. Cells are then exposed to the test substance, analyzed, and changes from baseline measured.
- FIG. 1 The data of the experiment are summarized in FIG. 1 .
- Cells which had been division arrested (P0P Ar 10 uM 5HT panel in FIG. 1 ) responded in a manner similar to those which were not (P0P Gr 10 uM 5HT panel in FIG. 1 ).
- “% positive” was calculated by taking the percentage in the positive region (i.e., cells demonstrating an increase in intracellular Ca ++ concentration that is greater than the baseline Ca ++ concentration of unstimulated cells) The “% positive” value was used to measure the extent of activation induced by serotonin.
- cell line M1WT3 (ATCC CRL 1985) was chosen. This cell line expresses muscaranic acetylcholine receptor. Experiments were designed to determine if known agonists induce Ca 2+ mobilization in these cells after growth arrest.
- M1WT3 cells were grown and treated, as set forth in example 1, supra. They were also treated with mitomycin C as described, and controls were prepared in exactly the same way.
- a Ca 2+ imaging device was used to inspect Ca 2+ mobilization visually. To do this, cells were loaded with “Fura-2” a fluorescent, Ca 2+ indicator. Cells were excited at 340 and 380 nm wavelengths, and emission ratios were monitored at 450 nm. Carbachol induced, Ca 2+ mobilization was observed, in M1WT3 cells, via changes in fluorescent emission ratios, rising from approximately 0.94 to 1.03 in individual cells ( FIG. 2 ). Mitomycin C pretreatment had no negative effect on the carbachol induced Ca 2+ response of the cells, when compared to cells not division-arrested (data not shown). It was shown that a larger percentage of division arrested cells responded to carbachol (data not shown), which is consistent with a more uniform cell population, resulting from the arrested division.
- G-protein coupled receptors elicit different pathways, depending on the G protein to which they couple.
- the experiments which follow were designed to show that seven-transmembrane receptors other than Gq coupled receptors function normally in growth arrested cells.
- HEK293 cells which had been transfected stably and overexpressed the ⁇ 2 adrenergic receptor (“ ⁇ 2AR”) (which is a Gs coupled, seven-transmembrane receptor) was used, in experiments designed to determine if isoproterenol would induce CRE-SEAP reporter activity.
- ⁇ 2AR ⁇ 2 adrenergic receptor
- the stably transfected cells were grown in DMEM with 10% FBS, and then were transiently transfected with a reporter plasmid, i.e., pCRE-SEAP.
- the cells were treated with mitomycin for 2 hours, 24 hours past transfection.
- the plasmid contained a CRE promoter, activity of which is elevated by cAMP, and which expresses higher levels of secreted, alkaline phosphatase (“SEAP”) upon activation of GPCRs, which use cAMP as a second messenger.
- SEAP alkaline phosphatase
- ⁇ 2ARs were activated with 100 uM of isoproterenol, and the level of SEAP activity was measured using commercially available products, 24 hours later.
- ⁇ 2 adrenergic receptor expressing cells responded to overnight treatment with 100 uM of isoproterenol, as measured by increased SEAP activity (approximately 25%).
- Growth arrested, ⁇ 2AR expressing cells displayed much lower background SEAP activity, which may be attributable to mitomycin C toxicity.
- overnight stimulation with isproterenol induced a 2.5 fold increase in SEAP activity, thus demonstrating that growth arrested cells still conduct largely intact signal transduction pathways down to the transcription response, and enzyme reporter assays can be carried out in division arrested cells.
- Miyotmycin C treatment caused significant toxicity to the P2AR expressing cells.
- a different method for arresting cell division i.e., gamma irradiation.
- Cells were either non-irradiated, and served as a control, or were irradiated at does ranging from 2Gy(Gray) to 8Gy. They were then treated with 100 uM isoproterenol, as described, supra. Reporter SEAP activity was measured, and compared to baseline activity (i.e., cells not treated with isoproterenol).
- FIG. 3 The results are depicted in FIG. 3 .
- Cells which were treated with 4Gy or more gamma irradiation showed far greater division arrest, with no noticeable cell proliferation for about a week. These cells show normal cell morphology and, when stimulated with isoproterenol, SEAP responses ranged from 4 to 6 fold over the baseline levels. These results were comparable to the cells that had not been division arrested, which responded 5.2 fold over baseline upon stimulation with isoproterenol.
- the foregoing discussion sets forth features of the invention, which relates, inter alia, to a method for screening for a substance of interest.
- the method comprises contacting the substance of interest with a sample of division arrested cells, and determining interaction between the division arrested cells and the substance of interest to determine one or more properties thereof. In this way, one can determine whether a substance of interest has efficacy as an antagonist, an agonist, an inhibitor, a stimulator, or a modulator of cells, is toxic to the cells, and so forth.
- division arrested as used herein is meant that the cells being used have been treated, by means known in the art, so that either their mitotic or meiotic cycle has been stopped, and cellular division can no longer take place.
- cells which express a particular molecule or molecules naturally, or cells transfected or transformed to express the molecule or molecules of interest may be used.
- Prokaryotic cells such as E. coli
- nucleic acid molecules such as those which encode a eukaryotic receptor
- eukaryotic cells such as NIH3T3 cells, HEK293 cells, CHO cells, and so forth, can all be used.
- Other types of nucleic acid molecules may be used, including DNA encoding any protein of interest, RNA and antisense molecules, including antisense DNA and antisense RNA.
- the cells may be cells which have been transduced with a molecule of interest, such as a peptide, and/or a protein containing a molecule such as a protein glycoprotein, lipoprotein, and so forth.
- a molecule of interest such as a peptide
- a protein containing a molecule such as a protein glycoprotein, lipoprotein, and so forth.
- the cell to be used is transformed or transfected with a nucleic acid molecule which performs a reporter function, such as SEAP, luciferase, green fluorescent protein, and so forth.
- a reporter function such as SEAP, luciferase, green fluorescent protein, and so forth.
- a reporter function such as SEAP, luciferase, green fluorescent protein, and so forth.
- the substance of interest may be tested directly, or it may be tested in a competitive assay, using a known antagonist or agonist of a receptor or other molecule of interest.
- an antibody can be tested for its efficacy as an antagonist of a molecule by mixing it with a known ligand for the molecule, and comparing a property of the target molecule with and without the presence of the antibody.
- the converse of this type of assay can also be carried out, where the antibody function is known, and the molecule of interest is not an antibody, or is in fact a second antibody.
- kits useful in screening for a substance of interest.
- kits may contain, e.g., a separate portion of each of (i) a substance which causes arrested division of a cell, and a substance known to interact with a target molecule of interest.
- the kit may also include cells transformed or transfected with the molecule of interest, or cells to be transformed or transfected and the agent used for transformation/transfection (e.g., an expression vector), or cells naturally expressing the target molecule of interest or other items. All of the variations set forth supra can be used in these kits. In cases where an additional function of the cells is to be described, that material can be included in the kit as well.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
- This invention relates to methods for screening for substances of interest. More particularly, it relates to screening assays which utilize cells in a division arrested state which, nonetheless, function effectively in assays where dividing cells would normally be used. The advantages of the system will be seen in the disclosure which follows.
- Cell based screening assays are tools well known to biologists. In the assays, one investigates compounds of interest to determine, e.g. if the compounds modulate one or more biological processes of interest.
- Among the cell based systems which are used are those which measure reporter activity, calcium activity assay, and so forth. These, and all other cell based assays are encompassed by the invention.
- One area where cell based screening assays have become widely accepted is the high throughput analysis of materials for use as pharmaceuticals. These assays are useful and desirable because compounds which are identified initially in biochemical assays have been known to fail as drug candidates later in the development process. The reasons for this are many. In some cases, the compound does not permeate the cell readily. In others, target binding capability is not predictive of the target modulating function, a feature that is, ultimately, a requirement of drug functions. Cell based screening assays are useful in that they address a number of problems associated with animal model testing (e.g., high expense, intensive labor, long assay period). High throughput cell based screening assays can be scaled up via technologies such as “FLIPR,” “Leedseeker,” “VIPR,” and fluorescent, high speed cell-imaging.
- In addition to assays such as those discussed supra, other commonly used, cell based assays involve enzyme-reporter systems, cell activity assays with a fluorescent or colorimetric readout, and so forth. An example of such an assay is a Ca2+ mobilization assay to measure G-protein coupled receptor activity with the dye “Fluo-4.”
- In addition to the advantages set forth supra, cell based assays have a distinct advantage in that they permit the user to determine the functional outcome of the use of compounds. Properly designed assays also permit the artisan to select against the toxic compounds, when screening for active ones.
- Carrying out high throughput, cell based assays present unique challenges to users. Unlike pure biochemical reagent like enzymes, proteins, and membrane receptor preparations, cells are live dynamic entities. Preparation and cultivation have to be tied to the actual screening process.
- Actively managed cell culture cycles have a recovery phase, when they are split from near confluent cultures, followed by an early log growth phase, then a mid log, and a late log phase, leading to a stationary phase if the culture is allowed to become confluent. Variances of the cellular processes and protein components at these different stages of growth and replication occur constantly during these cell cultures as cells cycle through mitosis. These variances must be expected to affect biological assays, and be a factor in the common phenomenon of variability in high throughput assays. One, but by no means the only example of this, relates to the length of time over which assays are run. There is generally an 8-36 hour period following the seeding of cells during which the assay is run. The cells in the particular culture go through different phases of their culture cycle during this time, and it is not usual for the cells to be at the same point in the cycle at the same time.
- Further, the miniaturization of cell based screening assays is progressing, with smaller and smaller numbers of cells being used. As this occurs, sensitivity of the assay to variability increases rapidly and dramatically.
- The critical factors of a good cell based screening assay are (i) a well validated target, (ii) a sensitive readout, and (iii) extremely high consistency of the cells that are used. The invention which is set forth in the disclosure which follows addresses this third issue. The consistent performance of the cells in an assay can be greatly affected by changes in the level of target expression as a result of increasing cell passage number. In addition, a well characterized population of cells can be division arrested, cryopreserved as a cell bank, and plated for an assay without any additional passaging of the cells. In fact, division arrested cells may be plated and used over a period of up to five (5) days without any further handling of the cells and without a significant change in cell based responses.
- Division arrested cells have been used in the art. Exemplary of this are Cho, et al, Biochem. Mol. Biol. Int. 42(5):949-56 (1997); Yao, et al, Mol. Pharmacol 57(3):422-30 (1997); Fueger, et al, J. Nucl. Med. 42(12):1856-62 (2001); Miller, et al, J. Exp. Med. 188(11):2033-45 (1998), and Kharbanda, et al, Nature 376 (6543):785-8 (1995). All of these references are incorporated by reference. Review of these, as well as other references will show that these studies concern characterization of the cells, rather than their use in assays of the type described herein, such as drug discovery, screening assays, and/or signal transduction assays, especially when these are carried out on a large scale, high throughput basis as is required for industrial application.
- These, as well as other features of the invention will be elaborated upon in the disclosure which follows.
-
FIG. 1 sets forth FACS scans depicting serotonin induction of Ca++ mobilization on division arrested cells, which are set forth in example 1. -
FIG. 2 shows the result of experiments, described in detail in example 2. It shows carbachol induced, Ca2+ mobilization, observed via changes in fluorescent emission ratios of Fura2 loaded into cells that were induced. -
FIG. 3 summarizes the result of experiments set forth in example 3, involving cells where division was arrested by irradiation, and which were treated with isoproterenol and reporter gene changes were measured. - These experiments describe screening assays designed to measure the induction of Ca2+ mobilization by serotonin in growth arrested, NIH3T3 cells.
- NIH3T3 cells were stably transfected with cDNA encoding the known receptor “5HT2c” using standard methods. For information on the receptor, see Julius, et al., Proc. Natl. Acad. Sci USA 87(3):928-32 (1990), incorporated by reference. After the transfection, and a preliminary screen to make sure that the transfection was successful, NIH3T3 cells which expressed the receptor were grown in DMEM, with L-glutamine without NaPyruvate, and with L-glucose (4500 mg/L), together with 1× penicillin-streptomycin solution and 10% (v/v) fetal bovine serum (FBS). This cell line is referred to as “NIH3T3-P0P.”
- In order to arrest the growth of the cells, they were exposed to 10 μg/ml of mitomycin C, for 2.5 hours. Mitomycin C is well known for its ability to arrest cell growth by blocking microtubule mobility, thereby arresting cell division. The cells were frozen, 2.5 hours after treatment, using standard protocols.
- As a control, cells which were not exposed to mitomycin C were frozen using the same procedure. Samples of both treated and control cells were thawed, using standard methods, and plated for 24 hours, prior to harvest. Harvesting was accomplished by adding 7 ml of an enzyme free, cell dissociation solution, (e.g., EnzymeFree Cell Dissociation Solution, Specialty Media, catalog number S-014) or with 0.5 mM EDTA, to cells. The number of cells used in each experiment was 4×105 cells/ml or about 4-4.5×106 total cells. Such solutions are widely available, and are well known to the skilled artisan. This treatment dissociated cells from the flask, and aggregates were then broken up by repeated pipetting of the suspensions, up and down in the flasks, so as to provide a good proportion of single cells, as this is necessary for the FACS analysis which followed.
- Cells were pelleted, and then resuspended in 6 ml of Indo-1 loading buffer.
- Cells were loaded with Indo-1 AM dye by adding 2 mg/ml of Indo-1 AM stock, in DMSO, to the cell suspensions to a final concentration of 10 ug/1.2 mls. Cells were exposed to Indo-1 AM for seven (7) minutes at room temperature and then diluted up to a final volume of 10 mls with Indo-1 loading buffer and pelleted.
- In order to measure and to analyze Ca2+ mobilization, a commercially available cell sorter was used. Excitation was set at 360 nm, and emissions were set at both 400 (±5 nm) and 500 (±20) nm. The emissions were monitored simultaneously, and the emission ratio at 400 nm/500 nm was used to report the intracellular rise of Ca2+ concentration. Untreated cells were used to set a baseline ratio.
- Cells were resuspended in a buffer and loaded into a syringe. Cells were injected continuously into the flow cytometer to be sampled and to provide a baseline value. A substance such as an antagonist can be used to pretreat the cells, with a second material, such as an agonist being injected continuously and simultaneously through, e.g., a second syringe, via a connecting means, such as a standard Y-connector. Cells are then exposed to the test substance, analyzed, and changes from baseline measured.
- The data of the experiment are summarized in
FIG. 1 . Cells which had been division arrested (P0P Ar 10 uM 5HT panel inFIG. 1 ) responded in a manner similar to those which were not (P0P Gr 10 uM 5HT panel inFIG. 1 ). In brief, “% positive” was calculated by taking the percentage in the positive region (i.e., cells demonstrating an increase in intracellular Ca++ concentration that is greater than the baseline Ca++ concentration of unstimulated cells) The “% positive” value was used to measure the extent of activation induced by serotonin. - Actively growing NIH3T3 cells which expressed 5HT2c showed a 50% Ca2+ response, while growth arrested cells showed a comparable 61.9% Ca++ response. Control experiments indicated that the response was receptor specific. To elaborate, parental NIH3T3 cells which were not transfected showed no fluorescence change when treated with serotonin (data not shown), while pretreatment with antagonist (10 uM Mesulergine) blocked serotonin induction completely (P0P Ar 10 uM 5HT, 10 uM Mes panel in
FIG. 1 ). Only 0.1% of Mesulergine pretreated cells responded to serotonin in Ca++ mobilization. - These experiments were carried out to determine if the principles proven in example 1, supra, were applicable to other receptors, such as other Gq coupled receptors. To test this, cell line M1WT3 (ATCC CRL 1985) was chosen. This cell line expresses muscaranic acetylcholine receptor. Experiments were designed to determine if known agonists induce Ca2+ mobilization in these cells after growth arrest.
- M1WT3 cells were grown and treated, as set forth in example 1, supra. They were also treated with mitomycin C as described, and controls were prepared in exactly the same way.
- A Ca2+ imaging device was used to inspect Ca2+ mobilization visually. To do this, cells were loaded with “Fura-2” a fluorescent, Ca2+ indicator. Cells were excited at 340 and 380 nm wavelengths, and emission ratios were monitored at 450 nm. Carbachol induced, Ca2+ mobilization was observed, in M1WT3 cells, via changes in fluorescent emission ratios, rising from approximately 0.94 to 1.03 in individual cells (
FIG. 2 ). Mitomycin C pretreatment had no negative effect on the carbachol induced Ca2+ response of the cells, when compared to cells not division-arrested (data not shown). It was shown that a larger percentage of division arrested cells responded to carbachol (data not shown), which is consistent with a more uniform cell population, resulting from the arrested division. - The results reported supra suggested that division arrested cells may be more consistent, over time, in screening assays. This was tested via a time-course cell imaging experiment. Division arrested and frozen cells were imaged as stimulated by serotonin 1, 3, 5 and 7 days following thawing of cells. Comparable percentage, and extent of Ca2+ response were found, as measured by a Fura 2 fluorescence 340/380 ratio change, on these different days, while significant changes in Ca2+ levels were found in growing populations on these different days.
- It is well known that G-protein coupled receptors elicit different pathways, depending on the G protein to which they couple. The experiments which follow were designed to show that seven-transmembrane receptors other than Gq coupled receptors function normally in growth arrested cells.
- To do this, HEK293 cells which had been transfected stably and overexpressed the μ2 adrenergic receptor (“μ2AR”) (which is a Gs coupled, seven-transmembrane receptor) was used, in experiments designed to determine if isoproterenol would induce CRE-SEAP reporter activity.
- The stably transfected cells were grown in DMEM with 10% FBS, and then were transiently transfected with a reporter plasmid, i.e., pCRE-SEAP. The cells were treated with mitomycin for 2 hours, 24 hours past transfection. The plasmid contained a CRE promoter, activity of which is elevated by cAMP, and which expresses higher levels of secreted, alkaline phosphatase (“SEAP”) upon activation of GPCRs, which use cAMP as a second messenger.
- Twenty-four hours after mitomycin C treatment, β2ARs were activated with 100 uM of isoproterenol, and the level of SEAP activity was measured using commercially available products, 24 hours later.
- Actively growing β2 adrenergic receptor expressing cells responded to overnight treatment with 100 uM of isoproterenol, as measured by increased SEAP activity (approximately 25%). Growth arrested, β2AR expressing cells displayed much lower background SEAP activity, which may be attributable to mitomycin C toxicity. Notwithstanding the lower background levels, overnight stimulation with isproterenol induced a 2.5 fold increase in SEAP activity, thus demonstrating that growth arrested cells still conduct largely intact signal transduction pathways down to the transcription response, and enzyme reporter assays can be carried out in division arrested cells.
- Miyotmycin C treatment caused significant toxicity to the P2AR expressing cells. As such, a different method for arresting cell division was tested, i.e., gamma irradiation.
- Cells were either non-irradiated, and served as a control, or were irradiated at does ranging from 2Gy(Gray) to 8Gy. They were then treated with 100 uM isoproterenol, as described, supra. Reporter SEAP activity was measured, and compared to baseline activity (i.e., cells not treated with isoproterenol).
- The results are depicted in
FIG. 3 . Cells which were treated with 4Gy or more gamma irradiation showed far greater division arrest, with no noticeable cell proliferation for about a week. These cells show normal cell morphology and, when stimulated with isoproterenol, SEAP responses ranged from 4 to 6 fold over the baseline levels. These results were comparable to the cells that had not been division arrested, which responded 5.2 fold over baseline upon stimulation with isoproterenol. - The foregoing discussion sets forth features of the invention, which relates, inter alia, to a method for screening for a substance of interest. The method comprises contacting the substance of interest with a sample of division arrested cells, and determining interaction between the division arrested cells and the substance of interest to determine one or more properties thereof. In this way, one can determine whether a substance of interest has efficacy as an antagonist, an agonist, an inhibitor, a stimulator, or a modulator of cells, is toxic to the cells, and so forth.
- By division arrested as used herein is meant that the cells being used have been treated, by means known in the art, so that either their mitotic or meiotic cycle has been stopped, and cellular division can no longer take place. There are many chemical, radiological, and other methods which can be used to accomplish the arrest of cellular division, and these need not be reiterated here, as the crux of the invention is not the act of causing the arrest of cell division, but the use of the arrested cells in assays as described.
- While it is possible to treat the cells in additional ways to arrest one or more additional biological processes, this is not necessary and, indeed, in many applications it will be desirable to have the cells function normally in all other ways but for the arrest in cell division.
- It will be seen by the skilled artisan that the type of cell used may vary. Any prokaryotic or eukaryotic cell may be used, in any cell based assay to determine the effect of a substance of interest on a cell type of interest.
- The nature of the cell type used will depend upon the particular type of assay to be run. To this end, cells which express a particular molecule or molecules naturally, or cells transfected or transformed to express the molecule or molecules of interest may be used. Prokaryotic cells, such as E. coli, which may be transformed with nucleic acid molecules, such as those which encode a eukaryotic receptor, and eukaryotic cells such as NIH3T3 cells, HEK293 cells, CHO cells, and so forth, can all be used. Other types of nucleic acid molecules may be used, including DNA encoding any protein of interest, RNA and antisense molecules, including antisense DNA and antisense RNA. Many methods are known for introducing the nucleic acid molecules to the host cells, such as via the use of recombinant viral vectors or other vectors that are adapted for the cell type of interest. Further, the cells may be cells which have been transduced with a molecule of interest, such as a peptide, and/or a protein containing a molecule such as a protein glycoprotein, lipoprotein, and so forth.
- In one embodiment of the invention, the cell to be used is transformed or transfected with a nucleic acid molecule which performs a reporter function, such as SEAP, luciferase, green fluorescent protein, and so forth. It is well known that one of ordinary skill in the art can transform or transfect cells with expression vectors which require activation of, e.g., a receptor to cause the promoter to which the reporter molecule is operably linked, to function. Since activation of the receptor molecule depends upon ligand receptor interaction, one can determine the effect of a putative ligand or “anti-ligand” by measuring the reporter molecule function, and comparing it to a control.
- Of course, it will be clear to the skilled artisan that it is also possible to measure receptor function directly, as was shown by the examples, supra. There are legions of receptors that are known, as is their effect when linked to a ligand molecule. Determination of one or more of these functions can be used as a determination of the effect of a substance of interest.
- The substance of interest may be tested directly, or it may be tested in a competitive assay, using a known antagonist or agonist of a receptor or other molecule of interest. For example, an antibody can be tested for its efficacy as an antagonist of a molecule by mixing it with a known ligand for the molecule, and comparing a property of the target molecule with and without the presence of the antibody. The converse of this type of assay can also be carried out, where the antibody function is known, and the molecule of interest is not an antibody, or is in fact a second antibody.
- The features of this invention also afford the user a kit useful in screening for a substance of interest. Such kits may contain, e.g., a separate portion of each of (i) a substance which causes arrested division of a cell, and a substance known to interact with a target molecule of interest. The kit may also include cells transformed or transfected with the molecule of interest, or cells to be transformed or transfected and the agent used for transformation/transfection (e.g., an expression vector), or cells naturally expressing the target molecule of interest or other items. All of the variations set forth supra can be used in these kits. In cases where an additional function of the cells is to be described, that material can be included in the kit as well.
- Other features of the invention will be clear to the skilled artisan, and need not be reiterated here.
Claims (21)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/363,983 US20060148007A1 (en) | 2002-09-20 | 2006-02-27 | Method for using division arrested cells in screening assays |
US11/775,708 US20080081327A1 (en) | 2002-09-20 | 2007-07-10 | Method for using division arrested cells in screening assays |
US12/138,218 US20080248516A1 (en) | 2002-09-20 | 2008-06-12 | Method for Using Division Arrested Cells in Screening Assays |
US12/685,223 US7960101B2 (en) | 2002-09-20 | 2010-01-11 | Method for using division arrested cells in screening assays |
US13/102,917 US20110275101A1 (en) | 2002-09-20 | 2011-05-06 | Method for using division arrested cells in screening assays |
US13/461,649 US20120276545A1 (en) | 2002-09-20 | 2012-05-01 | Method for using division arrested cells in screening assays |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/251,467 US7045281B2 (en) | 2002-09-20 | 2002-09-20 | Method for using division arrested cells in screening assays |
US11/363,983 US20060148007A1 (en) | 2002-09-20 | 2006-02-27 | Method for using division arrested cells in screening assays |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/251,467 Division US7045281B2 (en) | 2002-09-20 | 2002-09-20 | Method for using division arrested cells in screening assays |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/775,708 Continuation US20080081327A1 (en) | 2002-09-20 | 2007-07-10 | Method for using division arrested cells in screening assays |
US12/138,218 Continuation US20080248516A1 (en) | 2002-09-20 | 2008-06-12 | Method for Using Division Arrested Cells in Screening Assays |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060148007A1 true US20060148007A1 (en) | 2006-07-06 |
Family
ID=31992746
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/251,467 Expired - Lifetime US7045281B2 (en) | 2002-09-20 | 2002-09-20 | Method for using division arrested cells in screening assays |
US11/363,983 Abandoned US20060148007A1 (en) | 2002-09-20 | 2006-02-27 | Method for using division arrested cells in screening assays |
US11/775,708 Abandoned US20080081327A1 (en) | 2002-09-20 | 2007-07-10 | Method for using division arrested cells in screening assays |
US12/138,218 Abandoned US20080248516A1 (en) | 2002-09-20 | 2008-06-12 | Method for Using Division Arrested Cells in Screening Assays |
US12/685,223 Expired - Fee Related US7960101B2 (en) | 2002-09-20 | 2010-01-11 | Method for using division arrested cells in screening assays |
US13/102,917 Abandoned US20110275101A1 (en) | 2002-09-20 | 2011-05-06 | Method for using division arrested cells in screening assays |
US13/461,649 Abandoned US20120276545A1 (en) | 2002-09-20 | 2012-05-01 | Method for using division arrested cells in screening assays |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/251,467 Expired - Lifetime US7045281B2 (en) | 2002-09-20 | 2002-09-20 | Method for using division arrested cells in screening assays |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/775,708 Abandoned US20080081327A1 (en) | 2002-09-20 | 2007-07-10 | Method for using division arrested cells in screening assays |
US12/138,218 Abandoned US20080248516A1 (en) | 2002-09-20 | 2008-06-12 | Method for Using Division Arrested Cells in Screening Assays |
US12/685,223 Expired - Fee Related US7960101B2 (en) | 2002-09-20 | 2010-01-11 | Method for using division arrested cells in screening assays |
US13/102,917 Abandoned US20110275101A1 (en) | 2002-09-20 | 2011-05-06 | Method for using division arrested cells in screening assays |
US13/461,649 Abandoned US20120276545A1 (en) | 2002-09-20 | 2012-05-01 | Method for using division arrested cells in screening assays |
Country Status (8)
Country | Link |
---|---|
US (7) | US7045281B2 (en) |
EP (1) | EP1581645B1 (en) |
JP (1) | JP4317922B2 (en) |
AT (1) | ATE403739T1 (en) |
AU (1) | AU2003270073B2 (en) |
CA (1) | CA2499621A1 (en) |
DE (1) | DE60322743D1 (en) |
WO (1) | WO2004027374A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7045281B2 (en) * | 2002-09-20 | 2006-05-16 | Cell & Molecular Technologies, Inc. | Method for using division arrested cells in screening assays |
DK1573016T3 (en) * | 2002-10-04 | 2014-07-28 | Biomonitor Ltd | GENREPORTER ASSAY, KIT AND CELLS. |
ES2641271T3 (en) * | 2006-10-30 | 2017-11-08 | Le Centre National De La Recherche Scientifique (Cnrs) | Test gene, kit and cell assay with improved sensitivity and / or specificity to determine the level of TNF-alpha |
DK2220488T3 (en) * | 2007-10-30 | 2013-04-22 | Le Ct Nat De La Rech Scient Cnrs | Method for performing a test for neutralizing antibodies |
WO2009111572A2 (en) * | 2008-03-04 | 2009-09-11 | Le Centre Nationale De La Recherche Scientifique | Cell, method and kit for conducting an assay for neutralizing antibodies |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6875576B2 (en) * | 2001-02-15 | 2005-04-05 | Kosan Biosciences, Inc. | Method for evaluating therapeutic efficacy |
US6897067B2 (en) * | 2000-11-03 | 2005-05-24 | Regents Of The University Of Michigan | Surface transfection and expression procedure |
US7045281B2 (en) * | 2002-09-20 | 2006-05-16 | Cell & Molecular Technologies, Inc. | Method for using division arrested cells in screening assays |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5998136A (en) * | 1996-08-19 | 1999-12-07 | Arcaris, Inc. | Selection systems and methods for identifying genes and gene products involved in cell proliferation |
US20010046497A1 (en) * | 2000-04-21 | 2001-11-29 | Zhang Fang Liang | G-protein coupled receptor and methods |
JP2005505231A (en) | 2000-11-03 | 2005-02-24 | リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Surface transfection and expression methods |
US6723527B2 (en) * | 2001-10-26 | 2004-04-20 | Board Of Regents, The University Of Texas System | Methods for determining toxicity reversing agents |
-
2002
- 2002-09-20 US US10/251,467 patent/US7045281B2/en not_active Expired - Lifetime
-
2003
- 2003-09-04 WO PCT/US2003/027537 patent/WO2004027374A2/en active Search and Examination
- 2003-09-04 DE DE60322743T patent/DE60322743D1/en not_active Expired - Lifetime
- 2003-09-04 AU AU2003270073A patent/AU2003270073B2/en not_active Expired
- 2003-09-04 EP EP03751966A patent/EP1581645B1/en not_active Expired - Lifetime
- 2003-09-04 CA CA002499621A patent/CA2499621A1/en not_active Abandoned
- 2003-09-04 AT AT03751966T patent/ATE403739T1/en not_active IP Right Cessation
- 2003-09-04 JP JP2004537712A patent/JP4317922B2/en not_active Expired - Fee Related
-
2006
- 2006-02-27 US US11/363,983 patent/US20060148007A1/en not_active Abandoned
-
2007
- 2007-07-10 US US11/775,708 patent/US20080081327A1/en not_active Abandoned
-
2008
- 2008-06-12 US US12/138,218 patent/US20080248516A1/en not_active Abandoned
-
2010
- 2010-01-11 US US12/685,223 patent/US7960101B2/en not_active Expired - Fee Related
-
2011
- 2011-05-06 US US13/102,917 patent/US20110275101A1/en not_active Abandoned
-
2012
- 2012-05-01 US US13/461,649 patent/US20120276545A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6897067B2 (en) * | 2000-11-03 | 2005-05-24 | Regents Of The University Of Michigan | Surface transfection and expression procedure |
US6875576B2 (en) * | 2001-02-15 | 2005-04-05 | Kosan Biosciences, Inc. | Method for evaluating therapeutic efficacy |
US7045281B2 (en) * | 2002-09-20 | 2006-05-16 | Cell & Molecular Technologies, Inc. | Method for using division arrested cells in screening assays |
Also Published As
Publication number | Publication date |
---|---|
US7045281B2 (en) | 2006-05-16 |
US20040058329A1 (en) | 2004-03-25 |
ATE403739T1 (en) | 2008-08-15 |
US20080081327A1 (en) | 2008-04-03 |
DE60322743D1 (en) | 2008-09-18 |
US20110275101A1 (en) | 2011-11-10 |
US7960101B2 (en) | 2011-06-14 |
WO2004027374A2 (en) | 2004-04-01 |
CA2499621A1 (en) | 2004-04-01 |
US20120276545A1 (en) | 2012-11-01 |
EP1581645A2 (en) | 2005-10-05 |
JP4317922B2 (en) | 2009-08-19 |
AU2003270073B2 (en) | 2006-09-07 |
JP2006500025A (en) | 2006-01-05 |
AU2003270073A1 (en) | 2004-04-08 |
EP1581645A4 (en) | 2006-11-29 |
EP1581645B1 (en) | 2008-08-06 |
US20080248516A1 (en) | 2008-10-09 |
US20100203561A1 (en) | 2010-08-12 |
WO2004027374A3 (en) | 2005-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2476891C2 (en) | Identification of molecules modulating protein-protein interaction | |
US7960101B2 (en) | Method for using division arrested cells in screening assays | |
WO2003027634A2 (en) | Identification of modulatory molecules using inducible promoters | |
US7208290B2 (en) | Methods of co-expressing umami taste receptors and chimeric Gα15 variants | |
US20030170744A1 (en) | Multiplexed analysis of cellular responses using endogenous reporter genes | |
CN101636658A (en) | Fluorescence-based assay for detecting compounds for modulating the sodium-calcium exchanger (NCX) in 'forward mode' | |
KR102597698B1 (en) | A method for analysis of protein-protein interaction in cell based on p-body | |
US7229768B2 (en) | Universal G-protein coupled receptor reporter constructs | |
AU778648B2 (en) | Cells and assays | |
US20050033021A1 (en) | Chimeric Gatiphal 15 variants and their use in the analysis and discovery of modulators of G-protein coupled receptors | |
Lin et al. | Current Protocols in Protein Science Unit 26.5 (ms# CP-09-0158) TimeSTAMP tagging of newly synthesized proteins | |
US20060014188A1 (en) | System to detect inducible translocation | |
EP1546718A2 (en) | Method for determining the regulation of xenobiotic removal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: LIFE TECHNOLOGIES CORPORATION, CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:INVITROGEN CORPORATION;REEL/FRAME:025492/0398 Effective date: 20081121 Owner name: INVITROGEN CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CELL & MOLECULAR TECHNOLOGIES, INC.;REEL/FRAME:025489/0954 Effective date: 20070530 Owner name: CELL & MOLECULAR TECHNOLOGIES, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIVELLI, THOMAS;ZHONG, ZHONG;FEDERICI, MARK;AND OTHERS;REEL/FRAME:025491/0614 Effective date: 20020919 |